XML 65 R49.htm IDEA: XBRL DOCUMENT
v3.20.2

Acquisition, Collaborations And Other Arrangements (Details) $ / shares in Units, shares in Millions, $ in Millions |  |  |  | 3 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Jul. 17, 2020 USD ($) agreement | Jul. 13, 2020 USD ($) shares | Apr. 07, 2020 USD ($) $ / shares | Jun. 30, 2020 USD ($) | Jun. 30, 2019 USD ($) | Jun. 30, 2020 USD ($) | Jun. 30, 2019 USD ($) | Jun. 19, 2020 agreement | May 29, 2020 USD ($) shares
Acquisition, Collaborations and Other Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  | $ 4,524 | $ 165 | $ 4,621 | $ 291 |  |
Stock-based compensation expense |  |  |  |  |  | 309 | 317 |  |
Payments to acquire in process research and development |  |  |  |  |  | 4,804 | 239 |  |
Arcus |  |  |  |  |  |  |  |  |
Acquisition, Collaborations and Other Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Equity securities owned (in shares) | shares |  |  |  |  |  |  |  |  | 2.2
Equity securities in offering |  |  |  |  |  |  |  |  | $ 61
Pionyr |  |  |  |  |  |  |  |  |
Acquisition, Collaborations and Other Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Equity method investment, ownership percentage |  |  |  |  |  |  |  | 49.90% |
Number of agreements | agreement |  |  |  |  |  |  |  | 2 |
Subsequent Event | Arcus |  |  |  |  |  |  |  |  |
Acquisition, Collaborations and Other Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Equity securities owned (in shares) | shares |  | 6.0 |  |  |  |  |  |  |
Equity securities in offering |  | $ 200 |  |  |  |  |  |  |
Payments to acquire in process research and development |  | $ 175 |  |  |  |  |  |  |
Equity method investment, ownership percentage |  | 13.00% |  |  |  |  |  |  |
Future maximum research and development payments |  | $ 400 |  |  |  |  |  |  |
Collaborative term |  | 10 years |  |  |  |  |  |  |
Future maximum milestone payments |  | $ 1,200 |  |  |  |  |  |  |
Purchase period |  | 5 years |  |  |  |  |  |  |
Maximum percentage of outstanding stock allowed to be purchased |  | 35.00% |  |  |  |  |  |  |
Restriction period |  | 3 years |  |  |  |  |  |  |
Subsequent Event | Tizona |  |  |  |  |  |  |  |  |
Acquisition, Collaborations and Other Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Equity method investment, ownership percentage | 49.90% |  |  |  |  |  |  |  |
Number of agreements | agreement | 2 |  |  |  |  |  |  |  |
Payments to acquire equity method investments | $ 300 |  |  |  |  |  |  |  |
Option fee and potential future milestone payments | $ 1,300 |  |  |  |  |  |  |  |
Merger and Option Agreements | Subsequent Event | Pionyr |  |  |  |  |  |  |  |  |
Acquisition, Collaborations and Other Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Payments to acquire equity method investments |  | $ 275 |  |  |  |  |  |  |
Option exercise fee |  | 315 |  |  |  |  |  |  |
Potential future maximum milestone payments |  | 1,200 |  |  |  |  |  |  |
Research and Development Service Agreement | Subsequent Event | Pionyr |  |  |  |  |  |  |  |  |
Acquisition, Collaborations and Other Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Initial R&D funding |  | 80 |  |  |  |  |  |  |
Potential maximum future milestone payments |  | $ 115 |  |  |  |  |  |  |
Other Arrangements |  |  |  |  |  |  |  |  |
Acquisition, Collaborations and Other Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Upfront collaboration expenses related to other collaborative arrangements |  |  |  | $ 25 | 165 | $ 122 | 291 |  |
Cash payments made related to equity investments |  |  |  |  | $ 48 |  | $ 104 |  |
Forty Seven |  |  |  |  |  |  |  |  |
Acquisition, Collaborations and Other Arrangements [Line Items] |  |  |  |  |  |  |  |  |
Share price (usd per share) | $ / shares |  |  | $ 95.50 |  |  |  |  |  |
Total consideration, net of acquired cash |  |  | $ 4,700 |  |  |  |  |  |
Acquired in-process research and development expenses |  |  | 4,500 |  |  |  |  |  |
Assets acquired, net of cash |  |  | 202 |  |  |  |  |  |
Stock-based compensation expense |  |  | $ 144 |  |  |  |  |  |

X
- Definition Acquisition, Collaborations and Other Arrangements [Line Items] + References No definition available. + Details
Name: | gild_AcquisitionCollaborationsAndOtherArrangementsLineItems
Namespace Prefix: | gild_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition Cash Outflow Net Of Cash Acquired + References No definition available. + Details
Name: | gild_AssetAcquisitionCashOutflowNetOfCashAcquired
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Net of Cash + References No definition available. + Details
Name: | gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash Payments Made Related to Equity Investments + References No definition available. + Details
Name: | gild_CashPaymentsMadeRelatedToEquityInvestments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Term + References No definition available. + Details
Name: | gild_CollaborativeArrangementTerm
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Method Investment, Option Exercise Fee + References No definition available. + Details
Name: | gild_EquityMethodInvestmentOptionExerciseFee
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity Method Investment, Option Fee And Potential Future Milestone Payments + References No definition available. + Details
Name: | gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity Securities, FV-NI, Future Maximum Milestone Payments + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
Namespace Prefix: | gild_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Securities, FV-NI, Purchase Period + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIPurchasePeriod
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Securities, FV-NI, Research And Development, Future Maximum Payments + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIResearchAndDevelopmentFutureMaximumPayments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity Securities, FV-NI, Restriction Period + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIRestrictionPeriod
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial R&D Funding + References No definition available. + Details
Name: | gild_InitialRDFunding
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of Agreements + References No definition available. + Details
Name: | gild_NumberOfAgreements
Namespace Prefix: | gild_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potential Future Maximum Milestone Payments + References No definition available. + Details
Name: | gild_PotentialFutureMaximumMilestonePayments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Research And Development Future Maximum Payments + References No definition available. + Details
Name: | gild_ResearchAndDevelopmentFutureMaximumPayments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Upfront Collaboration Expenses Related to Other Collaborative Arrangements + References No definition available. + Details
Name: | gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Equity securities categorized neither as held-to-maturity nor trading which are intended be sold more than one year from the balance sheet date or operating cycle, if longer. + References No definition available. + Details
Name: | us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Balance held at close of period in number of shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14.Column B) -URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-12C.Column B) -URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12.Column B) -URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of noncash expense for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details
Name: | us-gaap_ShareBasedCompensation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncArcusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_MergerAndOptionAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_ResearchAndDevelopmentServiceAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gild_AssetAcquisitionAxis=gild_FortySevenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |